Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction

Acta Histochemica

Volumn 112, Issue 5, 2010, Pages 413-423

  Gray, Gillian A ^a   Patrizio, Mark ^a   Sherry, Lorcan ^a   Miller, Alyson A ^a   Malaki, Mohammed ^b   Wallace, Alison F ^a   Leiper, James M ^b   Vallance, Patrick ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ADMA; DDAH; L arginine; Myocardial infarction; Rats; SDMA

Indexed keywords

ARGININE; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENDOCARDIUM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MODIFICATION; ENZYME SUBSTRATE; HEART; HEART INFARCTION; HEART LEFT VENTRICLE INFARCTION; HEART MUSCLE CELL; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; INFLAMMATORY CELL; MALE; METHYLATION; NONHUMAN; PROTEIN CONTENT; PROTEIN LOCALIZATION; RAT; TISSUE HOMOGENATE; TISSUE LEVEL; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

EID: 77955270657     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2009.02.009     Document Type: Article

References (46)

1. Achan V., Ho H.K., Heeschen C., Stuehlinger M., Jang J.J., Kimoto M., et al. ADMA regulates angiogenesis: genetic and metabolic evidence. Vasc Med 2005, 10:7-14.
2. Achan V., Tran C.T., Arrigoni F., Whitley G.S., Leiper J.M., Vallance P. All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002, 90:764-769.
3. Arrigoni F.I., Vallance P., Haworth S.G., Leiper J.M. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003, 107:1195-1201.
4. Barouch L.A., Harrison R.W., Skaf M.W., Rosas G.O., Cappola T.P., Kobeissi Z.A., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002, 416:337-339.
5. Boger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003, 59:824-833.
6. Bulau P., Zakrzewicz D., Kitowska K., Leiper J., Gunther A., Grimminger F., et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol 2007, 292:L18-L24.
7. Cebasek V., Kubinova L., Ribaric S., Erzen I. A novel staining method for quantification and 3D visualisation of capillaries and muscle fibres. Eur J Histochem 2004, 48:151-158.
8. Czarnowska E., Kurzelewski M., Beresewicz A., Karczmarewicz E. The role of endogenous nitric oxide in inhibition of ischemia/reperfusion-induced cardiomyocyte apoptosis. Folia Histochem Cytobiol 2001, 39:179-180.
9. Dayoub H., Achan V., Adimoolam S., Jacobi J., Stuehlinger M.C., Wang B.Y., et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003, 108:3042-3047.
10. Drexler H., Kastner S., Strobel A., Studer R., Brodde O.E., Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998, 32:955-963.
11. Gillard B.K., Jones M.A., Marcus D.M. Glycosphingolipids of human umbilical vein endothelial cells and smooth muscle cells. Arch Biochem Biophys 1987, 256:435-445.
12. Gilson W.D., Epstein F.H., Yang Z., Xu Y., Prasad K.M., Toufektsian M.C., et al. Borderzone contractile dysfunction is transiently attenuated and left ventricular structural remodeling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice. J Am Coll Cardiol 2007, 50:1799-1807.
13. Hasegawa K., Wakino S., Tanaka T., Kimoto M., Tatematsu S., Kanda T., et al. Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:1488-1494.
14. Hasegawa K., Wakino S., Tatematsu S., Yoshioka K., Homma K., Sugano N., et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 2007, 101:e2-e10.
15. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
16. Jacobi J., Sydow K., von Degenfeld G., Zhang Y., Dayoub H., Wang B., et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005, 111:1431-1438.
17. Kostourou V., Robinson S.P., Cartwright J.E., Whitley G.S. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002, 87:673-680.
18. Laussmann T., Janosi R.A., Fingas C.D., Schlieper G.R., Schlack W., Schrader J., et al. Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow. FASEB J 2002, 16:628-630.
19. Leiper J., Murray-Rust J., McDonald N., Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002, 99:13527-13532.
20. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007, 13:198-203.
21. Leiper J.M., Santa Maria J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999, 343(Pt 1):209-214.
22. MacAllister R.J., Fickling S.A., Whitley G.S., Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994, 112:43-48.
23. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996, 119:1533-1540.
24. Masuda H., Tsujii T., Okuno T., Kihara K., Goto M., Azuma H. Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1730-R1738.
25. Masuda H., Tsujii T., Okuno T., Kihara K., Goto M., Azuma H. Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia. Br J Pharmacol 2001, 133:97-106.
26. Miller A.A., Megson I.L., Gray G.A. Inducible nitric oxide synthase-derived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure. Br J Pharmacol 2000, 131:29-36.
27. Murray-Rust J., Leiper J., McAlister M., Phelan J., Tilley S., Santa Maria J., et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001, 8:679-683.
28. Ogawa T., Kimoto M., Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989, 264:10205-10209.
29. Ono Y., Ono H., Matsuoka H., Fujimori T., Frohlich E.D. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999, 34:609-616.
30. Palm F., Onozato M.L., Luo Z., Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007, 293:H3227-H3245.
31. Pepys M.B., Hirschfield G.M., Tennent G.A., Gallimore J.R., Kahan M.C., Bellotti V., et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440:1217-1221.
32. Saito T., Hu F., Tayara L., Fahas L., Shennib H., Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 2002, 283:H339-H345.
33. Shah A.M., MacCarthy P.A. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000, 86:49-86.
34. Small G.R., Hadoke P.W., Sharif I., Dover A.R., Armour D., Kenyon C.J., et al. Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA 2005, 102:12165-12170.
35. Smith C.L., Birdsey G.M., Anthony S., Arrigoni F.I., Leiper J.M., Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 2003, 308:984-989.
36. Stuhlinger M.C., Conci E., Haubner B.J., Stocker E.M., Schwaighofer J., Cooke J.P., et al. Asymmetric dimethyl l-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res 2007, 75:417-425.
37. Stuhlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001, 104:2569-2575.
38. Sumeray M.S., Rees D.D., Yellon D.M. Infarct size and nitric oxide synthase in murine myocardium. J Mol Cell Cardiol 2000, 32:35-42.
39. Takimoto Y., Aoyama T., Keyamura R., Shinoda E., Hattori R., Yui Y., et al. Differential expression of three types of nitric oxide synthase in both infarcted and non-infarcted left ventricles after myocardial infarction in the rat. Int J Cardiol 2000, 76:135-145.
40. Teerlink T., Nijveldt R.J., de Jong S., van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002, 303:131-137.
41. Tran C.T., Fox M.F., Vallance P., Leiper J.M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 2000, 68:101-105.
42. Usui M., Matsuoka H., Miyazaki H., Ueda S., Okuda S., Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998, 62:2425-2430.
43. Vallance P., Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004, 24:1023-1030.
44. Wang D., Yang X.P., Liu Y.H., Carretero O.A., LaPointe M.C. Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. Am J Hypertens 1999, 12:174-182.
45. Wildhirt S.M., Dudek R.R., Suzuki H., Bing R.J. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol 1995, 50:253-261.
46. Wojciak-Stothard B., Torondel B., Tsang L.Y., Fleming I., Fisslthaler B., Leiper J.M., et al. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 2007, 120:929-942.